Stada Expands In Ukraine With Biopharma Deal
Acquisition Of Prescription And Consumer Units To Close By Year End
Stada has struck a deal to acquire the prescription and consumer health businesses of Ukraine’s Biopharma, including local manufacturing operations and around 300 new staff. Biopharma will retain its blood plasma-based business.
You may also be interested in...
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.
Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.